Skip to main content
IMDX
NASDAQ Life Sciences

Graftassuredx 迈向 FDA 提交，Insight Molecular Diagnostics 完成关键里程碑

feedReported by Reuters
Sentiment info
Positive
Importance info
8
Price
$4.94
Mkt Cap
$158.806M
52W Low
$2.33
52W High
$8.51
Market data snapshot near publication time

summarizeSummary

Insight Molecular Diagnostics Inc.宣布其 Graftassuredx 产品已完成关键里程碑，距离 FDA 提交更近了一步。这种发展是公司的一个重大积极步骤，尤其是在最近与 Quest Diagnostics 签订战略标本收集协议之后，这可能会促进未来的检测或商业化工作。对于一家这种规模的公司来说，将产品推向监管批准是一个重要事件，表明公司在潜在的市场进入和收入生成方面取得了进展。交易者现在将关注官方的 FDA 提交和随后的监管决定作为下一个主要催化剂。

在该公告发布时，IMDX的交易价格为$4.94，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1.6亿。 52周交易区间为$2.33至$8.51。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed IMDX - Latest Insights

IMDX
Apr 27, 2026, 7:14 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Broadwood Partners Increases Stake to 39.7%, Signals Intent for Shareholder Value Creation
Sentiment: Positive
View Wiseek Article
IMDX
Apr 27, 2026, 7:08 PM EDT
Filing Type: 4
Importance Score:
9
Broadwood Partners, a 10% owner, significantly increases stake in Insight Molecular Diagnostics with over $2M in new purchases
Sentiment: Positive
View Wiseek Article
IMDX
Apr 20, 2026, 7:24 PM EDT
Filing Type: 4
Importance Score:
8
10% Owner Broadwood Partners Increases Stake with $652K Open Market Purchase
Sentiment: Positive
View Wiseek Article
IMDX
Apr 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
iMDx's GraftAssure Assay Gains Momentum with New Clinical Data, FDA Submission Details
Sentiment: Positive
View Wiseek Article
IMDX
Mar 26, 2026, 4:13 PM EDT
Filing Type: 10-K
Importance Score:
8
Insight Molecular Diagnostics Resolves Going Concern, Secures $24.6M in New Capital, and Submits Key Product to FDA
Sentiment: Positive
View Wiseek Article
IMDX
Mar 26, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
Insight Molecular Diagnostics Submits Key Transplant Diagnostic for FDA Review, Reports Q4 Results
Sentiment: Positive
View Wiseek Article
IMDX
Mar 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Second Study Affirms iMDx GraftAssure Superiority, Enabling First-Ever Transplant Rejection 'Rule-In' Option
Sentiment: Positive
View Wiseek Article
IMDX
Mar 03, 2026, 8:07 AM EST
Source: Reuters
Importance Score:
8
Graftassuredx Advances Toward FDA Submission as Insight Molecular Diagnostics Completes Key Milestones
Sentiment: Positive
View Wiseek Article
IMDX
Feb 26, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Insight Molecular Diagnostics Partners with Quest Diagnostics for GraftAssureCore™ Test Collection
Sentiment: Positive
View Wiseek Article
IMDX
Feb 12, 2026, 7:52 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Activist Investor Broadwood Partners Increases Stake to 37.4% with $3M Premium Purchase
Sentiment: Positive
View Wiseek Article